معرفی
Thomas Kosten is an Adjunct Professor in the Department of Psychiatry at Yale School of Medicine, Yale University. His research focuses on addiction medicine, immunotherapies for substance use disorders, and clinical interventions for mental health conditions like depression and PTSD. He collaborates extensively with researchers globally, including work on anti-addiction vaccines and novel treatments for opioid and alcohol use disorders. Recent studies include evaluating the long-term safety of esmethadone for major depressive disorder and investigating plasma microRNAs as biomarkers for vaccine efficacy in addiction.
Key areas of expertise include translational medicine, neuropsychopharmacology, and clinical trial design. His work often integrates interdisciplinary approaches, such as combining neurostimulation techniques (e.g., transcranial magnetic stimulation) with pharmacological interventions to address treatment-resistant depression. Kosten also explores the pharmacogenetic impact of medications like celecoxib in schizophrenia and the use of machine learning to predict adverse events in comorbid PTSD and alcohol use disorder patients.
Publications highlight contributions to vaccine development for fentanyl and other opioids, lithium’s role in reducing impulsive behavior in high-risk suicide populations, and leveraging natural language processing for PTSD patient assessment. Collaborations with institutions worldwide underscore his commitment to advancing evidence-based therapies for complex psychiatric and addiction-related conditions.